In vitro pharmacological characterization of AM1241: A protean agonist at the cannabinoid CB 2 receptor?

British Journal of Pharmacology

Volumn 149, Issue 2, 2006, Pages 145-154

  Yao, B B ^a   Mukherjee, S ^a   Fan, Y ^a   Garrison, T R ^a   Daza, A V ^a   Grayson, G K ^a   Hooker, B A ^a   Dart, M J ^a   Sullivan, J P ^a   Meyer, M D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

AM1241; Cannabinoid; CB 2 receptor; GPCR; Protean agonist; Receptor constitutive activity

Indexed keywords

(2 IODO 5 NITROPHENYL)[1 (1 METHYLPIPERIDIN 2 YLMETHYL) 1H INDOL 3 YL]METHANONE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLASE; ENZYME; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PIPERIDINE DERIVATIVE; REAGENT; RECOMBINANT RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG;

ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; FLUOROMETRIC IMAGE PLATE READER FUNCTIONAL ASSAY; FLUOROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; RECEPTOR AFFINITY;

CANNABINOIDS; CELL LINE; HUMANS; RECEPTOR, CANNABINOID, CB2;

EID: 33748490903     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706838     Document Type: Article

References (53)

1. Baker D, Pryce G, Giovannoni G, Thompson AJ (2003). The therapeutic potential of cannabis. Lancet Neurol 2: 291-298.
2. 3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat. Neuropharmacol 48: 246-251.
3. Barth F, Casellas P, Congy C, Martinez S, Rinaldi M, Anne-Archard G (1995). Preparation of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxamide as a cannabinoid receptor antagonist. European Patent Appl. EP 656354.
4. Barth F, Casellas P, Millan J, Oustric D, Rinaldi M, Sarran M (1997). 3-Pyrazolecarboxamide derivatives having cannabinoid receptor. PCT Patent Appl. WO 9721682.
5. i-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett 449: 61-65.
6. 2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55: 473-480.
7. Brown AE, Ueno S, Suen K, Dowell SJ, Wise A (2005). Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. ICRS 15th Symposium on the Cannabinoids. Clearwater, Florida. pp 16.
8. Brown SM, Wager-Miller J, Mackie K (2002). Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim Biophys Acta 1576: 255-264.
9. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK et al. (2000). Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57: 125-134.
10. α. Nature 363: 274-276.
11. Croxford JL (2003). Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17: 179-202.
12. 2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311-2320.
13. Fox A, Bevan S (2005). Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Invest Drugs 14: 695-703.
14. Fox A, Kesingland A, Gentry C, Mcnair K, Patel S, Urban L et al. (2001). The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
15. 3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100: 11086-11091.
16. Goutopoula A, Makriyannis A (2003). From cannabis to cannabinergic: new therapeutic opportunities. Pharmacol Ther 95: 103-117.
17. Griffin G, Tao Q, Abood ME (2000). Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. J Pharmacol Exp Ther 292: 886-894.
18. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
19. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
20. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, DevaneWA et al. (2002). International union of pharmacology XXVII classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
21. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47: 345-358.
22. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
23. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098.
24. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76: 189-199.
25. Jansson CC, Kukkonen JP, Näsman J, Huifang G, Wurster S, Virtanen R et al. (1998). Protean agonism at alpha2A-adrenoceptors. Mol Pharmacol 53: 963-968.
26. Karnik SS, Gogonea C, Patil S, Saad Y, Takezako T (2003). Activation of G-protein-coupled receptors: a common molecular mechanism. Trends Endocrinol Metab 14: 431-437.
27. Kenakin T (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611.
28. Kenakin T (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
29. Lauckner JE, Reyes F, Xu C, Hille B, Stella N, Mackie K (2005). Distribution and functional characterization of a novel cannabinoid receptor. Society for Neuroscience 35th Annual Meeting Washington, DC. pp 491.4.
30. Makriyannis A, Deng H (2001). Receptor selective cannabimimetic aminoalkylindoles. PCT Patent Appl. WO 02/060447 A1.
31. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
32. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62-67.
33. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
34. Milligan G (2003). Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64: 1271-1276.
35. 2 cannabinoid receptors. Eur J Pharmacol 505: 1-9.
36. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
37. Pauwels PJ, Rauly I, Wurch T, Colpaert FC (2002). Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by coexpression with different G alpha protein subunits. Neuropharmacology 42: 855-863.
38. Perez DM, Karnik SS (2005). Multiple signaling states of G-proteincoupled receptors. Pharmacol Rev 57: 147-161.
39. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
40. Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S et al. (2005). Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105: 1214-1221.
41. Prather PL (2004). Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors. Science's STKE 215: 1-3.
42. 2 cannabinoid receptors. Anesthesiology 99: 955-960.
43. Reyes F, Lauckner JE, Xu C, Mackie K, Stella N (2005). Initial characterization of a novel cannabinoid receptor in glial cells. In Society for Neuroscience 35th Annual Meeting Washington, DC. pp 491.9.
44. Rice AS (2001). Cannabinoids and pain. Curr Opin Invest Drugs 2: 399-414.
45. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, Heng HH et al. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64: 193-198.
46. Scott DA, Wright CE, Angus JA (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109: 124-131.
47. Seifert R, Wenzel-Seifert K (2002). Constitutive activity of G-proteincoupled receptors: cause of disease and common property of wildtype receptors. Naunyn Schmiedeberg's Arch Pharmacol 366: 381-416.
48. 2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307: 132-136.
49. Sjogren S, Ryberg E, Lindblom A, Larsson N, Astrand A, Hjorth S et al. (2005). A new receptor for cannabinoid ligands. In ICRS 15th Symposium on the Cannabinoids. Clearwater: Florida, pp 106.
50. 2. In Society for Neuroscience 35th Annual Meeting Washington, DC; pp 634.1.
51. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672.
52. Walter L, Franklin A,Witting A,Wade C, Xie Y, Kunos G et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405.
53. Wess J (1998). Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 80: 231-264.